|
gptkbp:instanceOf
|
antibiotic class
|
|
gptkbp:administeredBy
|
oral
intravenous
|
|
gptkbp:approvedBy
|
gptkb:norfloxacin
|
|
gptkbp:blackBoxWarning
|
peripheral neuropathy
CNS effects
tendinitis
|
|
gptkbp:category
|
fourth-generation antibiotic
second-generation antibiotic
third-generation antibiotic
|
|
gptkbp:contraindication
|
children
pregnancy
|
|
gptkbp:developedBy
|
gptkb:nalidixic_acid
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:drugInteraction
|
gptkb:theophylline
gptkb:warfarin
antacids
|
|
gptkbp:eliminatedIn
|
renal
hepatic
|
|
gptkbp:example
|
gptkb:moxifloxacin
gptkb:levofloxacin
gptkb:ofloxacin
ciprofloxacin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fluoroquinolones
|
|
gptkbp:mechanismOfAction
|
inhibit DNA gyrase
inhibit topoisomerase IV
|
|
gptkbp:notEffectiveAgainst
|
gptkb:MRSA
anaerobes
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:regulates
|
gptkb:FDA
|
|
gptkbp:resistantTo
|
efflux pumps
mutations in DNA gyrase
|
|
gptkbp:riskFactor
|
gptkb:Clostridioides_difficile_infection
antibiotic resistance
|
|
gptkbp:sideEffect
|
QT prolongation
gastrointestinal upset
CNS effects
tendon rupture
|
|
gptkbp:spectrumOfActivity
|
broad-spectrum
|
|
gptkbp:structureContains
|
fluorine atom
quinolone core
|
|
gptkbp:usedFor
|
gptkb:prostatitis
skin infections
urinary tract infections
bacterial infections
gastrointestinal infections
respiratory tract infections
bone and joint infections
|
|
gptkbp:bfsParent
|
gptkb:Gonorrhea
|
|
gptkbp:bfsLayer
|
5
|